Anavex Nominates Two New Directors, Escalates Proxy Fight with Activist PVG
AVXL sits 22% above its 52-week low of $2.255.
Summary
Anavex is refreshing its board with two new independent nominees, Gautam Patel and Adrian Senderowicz, who bring life sciences and regulatory experience. The move comes amid a proxy battle with activist PVG Asset Management, which is seeking to replace the entire board. The company also confirmed that former CEO Christopher Missling and director Steffen Thomas will not be renominated, effectively removing them after the annual meeting. This follows a turbulent period including the CEO's termination for cause, a Nasdaq delinquency notice, and a recent narrower quarterly loss. The board refresh and proxy filing signal an effort to stabilize governance and counter the activist challenge, with the annual meeting date still to be set.
At the time of this announcement, AVXL was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.8M. The 52-week trading range was $2.26 to $12.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.